# Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

> **NCT05186818** · PHASE3 · COMPLETED · sponsor: **Cytokinetics** · enrollment: 282 (actual)

## Conditions studied

- Obstructive Hypertrophic Cardiomyopathy (oHCM)

## Interventions

- **DRUG:** Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)
- **DRUG:** Placebo to match aficamten

## Key facts

- **NCT ID:** NCT05186818
- **Lead sponsor:** Cytokinetics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-01
- **Primary completion:** 2023-11-10
- **Final completion:** 2023-12-18
- **Target enrollment:** 282 (ACTUAL)
- **Last updated:** 2026-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05186818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05186818, "Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05186818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*